{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:37:51Z","timestamp":1789994271609,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","content-domain":{"domain":["cell.com","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.molmed.2014.02.002","type":"journal-article","created":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T23:47:44Z","timestamp":1394581664000},"page":"315-321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Hepatitis C treatment: an incipient therapeutic revolution"],"prefix":"10.1016","volume":"20","author":[{"given":"Andrew S.","family":"deLemos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2014.02.002_bib0005","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.molmed.2014.02.002_bib0015","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0020","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1053\/j.gastro.2010.12.032","article-title":"Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection","volume":"140","author":"Kanwal","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0030","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/hep.26218","article-title":"Chronic hepatitis C virus (HCV) disease burden and cost in the United States","volume":"57","author":"Razavi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-157-9-201211060-00529","article-title":"Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention","volume":"157","author":"Smith","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.molmed.2014.02.002_bib0040","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/hep.25510","article-title":"Economic model of a birth cohort screening program for hepatitis C virus","volume":"55","author":"McGarry","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0045","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2014.02.002_bib0050","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2014.02.002_bib0055","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) \u2013 NCT01514890","volume":"59","author":"Hezode","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2014.02.002_bib0060","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1016\/S0168-8278(13)60820-X","article-title":"HCV-TARGET: A longitudinal, observational study of North American patients with chronic hepatitis C (HCV) treated with boceprevir or telaprevir [abstract]","volume":"58","author":"Fried","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2014.02.002_bib0065","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2014.02.002_bib0070","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.molmed.2014.02.002_bib0075","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.1016\/S0168-8278(13)61424-5","article-title":"Simeprevir (TMC435) with peginterferon\/ribavirin for chronic HCV genotype-1 infection in treatment-na\u00efve patients: results from QUEST-1, a phase III trial [abstract]","volume":"58","author":"Jacobson","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2014.02.002_bib0080","doi-asserted-by":"crossref","first-page":"S568","DOI":"10.1016\/S0168-8278(13)61412-9","article-title":"Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-na\u00efve patients: results from QUEST-2, a phase III trial [abstract]","volume":"58","author":"Manns","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2014.02.002_bib0085","first-page":"737A","volume":"58","author":"Forns","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0090","first-page":"734A","article-title":"A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon \u03b1-2a and rib-avirin in treatment-na\u00efve patients with chronic hepatitis C genotype-1 infection [abstract]","volume":"58","author":"Jensen","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0095","first-page":"742A","article-title":"STARTVerso3: A randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon \u03b1-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection [abstract]","volume":"58","author":"Jacobson","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0100","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2014.02.002_bib0105","first-page":"733A","article-title":"Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE Trial [abstract]","volume":"58","author":"Zeuzem","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2014.02.002_bib0115","first-page":"1379A","article-title":"SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: The COSMOS Study [abstract]","volume":"58","author":"Jacobson","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2014.02.002_bib0125","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2014.02.002_bib0130","first-page":"313A","article-title":"All-oral combination of daclatasvir plus asunaprevir in interferon ineligible naive\/intolerant and nonresponder Japanese patients chronically infected with HCV genotype 1b: results from a Phase 3 trial [oral presentation]","volume":"58","author":"Chayama","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0135","first-page":"749A","article-title":"Analysis of HCV resistance variants in a Phase 3 trial of daclatasvir combined with asunaprevir for Japanese patients with genotype 1b infection [abstract]","volume":"58","author":"McPhee","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0140","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2013.10.057","article-title":"Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection","volume":"146","author":"Everson","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0230","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2014.02.002_bib0150","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1306227","article-title":"Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2014.02.002_bib0155","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","article-title":"Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis","volume":"33","author":"Graham","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.molmed.2014.02.002_bib0160","first-page":"313A","article-title":"All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1) [oral presentation]","volume":"58","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0165","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/lt.23482","article-title":"Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation","volume":"18","author":"Fontana","year":"2012","journal-title":"Liver Transpl."},{"key":"10.1016\/j.molmed.2014.02.002_bib0170","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/ajt.12209","article-title":"Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C","volume":"13","author":"Fontana","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.molmed.2014.02.002_bib0175","first-page":"314A","article-title":"Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation [oral presentation]","volume":"58","author":"Curry","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0180","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-\u03b1 and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2014.02.002_bib0185","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study","volume":"138","author":"Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0190","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2014.02.002_bib0195","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-\u03b1 and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2014.02.002_bib0200","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2014.02.002_bib0205","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1053\/j.gastro.2010.07.005","article-title":"A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice","volume":"139","author":"Tillmann","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0210","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.23912","article-title":"IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C","volume":"52","author":"Urban","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0215","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1053\/j.gastro.2012.01.046","article-title":"Genetic factors and hepatitis C virus infection","volume":"142","author":"Thompson","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0220","first-page":"752A","article-title":"Virologic response rates to sofosbuvir-containing regimens are similar in patients with and without traditional negative predictive factors: a retrospective analysis of Phase 3 data [abstract]","volume":"58","author":"Mangia","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2014.02.002_bib0225","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2012.02.015","article-title":"Anti-hepatitis C virus drugs in development","volume":"142","author":"Schaefer","year":"2012","journal-title":"Gastroenterology"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491414000239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491414000239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T04:53:58Z","timestamp":1538801638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491414000239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1471491414000239"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2014.02.002","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C treatment: an incipient therapeutic revolution","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2014.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}